Safety, antiviral activity, and pharmacokinetics of long-acting cabotegravir plus long-acting rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): week 96 and end-of-study results from a multinational, phase 1/2, single-arm trial.
BACKGROUND Week 24 and week 48 study data from the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT 2017)/More Options for Children and Adolescents (MOCHA) trial supported the use of long-acting cabotegravir plus long-acting rilpivirine, given every 4 weeks or 8 weeks, per the adult dos...